News Sentiment

AGEN sentiment intelligence

Agenus Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.35 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

85/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-4.0% over one week, +1.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Agenus (AGEN) Could Be 83% Undervalued On Phase 1b Data And $340 Million Raise

Market Reaction

Price moving ahead of tone

69/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 85/100 classification
One-week reaction -4.0% Price reacting lower
Trend fit Trend inactive 1.5% over four weeks
Fair value -59.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 35
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
Stock Titan 7
simplywall.st 4
Oncodaily 4
TradingView 4
Investing.com 4
Benzinga 3
Business Wire 3

Event Lens

What the news is about

Classified themes
Market update 40
Earnings 11
Balance sheet 4
Deals and strategy 2
Analyst action 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-59 of 59
Business Wire Direct company coverage

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer

Agenus Inc. has announced an oversubscribed private placement of up to $340 million to fund its registrational Phase 3 ROBBIN trial for neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer. This financing includes $85 million upfront and

Tone
Positive 72/100
Event
Market update
Published
13 Jul 2026 09:41
Source
Business Wire
Stock Titan Direct company coverage

Director Wright of Agenus (NASDAQ: AGEN) granted deferred stock units

Agenus director Timothy Wright was granted 2,267.765 Deferred Stock Units on July 1, 2026, as routine compensation. These units, valued at $3.583 each based on the prior quarter's average closing price, are tied to the company's common stock and will typically be settled in share

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 15:10
Source
Stock Titan
Stock Titan Direct company coverage

Agenus (NASDAQ: AGEN) director Harrison awarded 8,547 shares as board compensation

Agenus (NASDAQ: AGEN) director Thomas L. Harrison was awarded 8,547 shares of common stock on July 1, 2026, as board compensation. These shares were acquired under the company’s Board Compensation Election Policy, allowing directors to receive fees in stock. This grant increased

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 15:10
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 4 Agenus Inc For: 7 July By Investing.com

This article reports that a Form 4 filing for Agenus Inc. was made on July 7th. It includes the stock symbol AGEN and its current price performance, showing a 2.64% increase. The article itself is very brief, mainly serving as a notification about the regulatory filing.

Tone
Neutral 50/100
Event
Regulatory and legal
Published
07 Jul 2026 14:39
Source
Investing.com Nigeria
Oncodaily Direct company coverage

Agenus Reports Landmark 3-Year OS Data for BOT+BAL in Refractory MSS mCRC at ESMO GI

Agenus announced three-year overall survival data for its botensilimab (BOT) and balstilimab (BAL) combination therapy in refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The Phase 1b data, presented at ESMO GI 2026, show

Tone
Positive 90/100
Event
Market update
Published
07 Jul 2026 12:09
Source
Oncodaily
AllSci Direct company coverage

Agenus Achieves 33% Three-Year Survival in Colorectal Cancer

Agenus Inc. reported promising three-year overall survival data for botensilimab in refractory microsatellite-stable (MSS) metastatic colorectal cancer, with 33% of patients alive at 36 months – a significant improvement over historical outcomes in this challenging disease. While

Tone
Positive 67/100
Event
Market update
Published
06 Jul 2026 23:15
Source
AllSci
TradingView Direct company coverage

Agenus Extends $5.09M Notes to 2027, Lengthens Warrants to 2031 and Issues New D Warrants

Agenus has extended $5.09 million in 2015 senior subordinated notes to February 18, 2027, maintaining existing terms. The company also prolonged the expiration dates of its 2022 A and B Warrants and 2025 C Warrants to June 25, 2031, and issued new 2026 D Warrants for 56,525 share

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 20:41
Source
TradingView
Stock Titan Direct company coverage

Agenus (NASDAQ: AGEN) extends note maturity and long-dated warrants

Agenus Inc. (NASDAQ: AGEN) has extended the maturity date of $5.09 million in senior subordinated promissory notes from June 20, 2026, to February 18, 2027. Additionally, the company extended the expiration dates of three series of existing warrants covering 165,000 shares of com

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 20:41
Source
Stock Titan
BioPharm International Direct company coverage

Agenus BOT+BAL Shows 33% Three-Year Survival in Immunotherapy-Resistant Colorectal Cancer

Agenus announced that its BOT+BAL combination therapy achieved a 33% three-year overall survival rate in patients with refractory microsatellite-stable metastatic colorectal cancer (MSS mCRC) without active liver metastases. This data, to be presented at ESMO GI 2026, demonstrate

Tone
Positive 72/100
Event
Market update
Published
06 Jul 2026 18:41
Source
BioPharm International
grafa.com Direct company coverage

Agenus reports 3-year survival data in colorectal cancer study

Agenus reported positive 3-year Phase 1b data for its botensilimab and balstilimab combination in metastatic colorectal cancer, showing a median overall survival of 21.2 months and a 33% 3-year overall survival rate. The study observed no new safety signals and 98% resolution of

Tone
Positive 77/100
Event
Market update
Published
06 Jul 2026 15:41
Source
grafa.com
Stock Titan Direct company coverage

Agenus (AGEN) director Armen takes June 2026 salary in 5,364 company shares

Agenus Inc. director Dr. Garo H. Armen opted to receive his June 2026 salary in 5,364 shares of company common stock, valued at $3.03 per share, instead of cash. These shares were fully vested upon issuance under the company's 2019 Equity Incentive plan, bringing his direct holdi

Tone
Neutral 50/100
Event
Balance sheet
Published
30 Jun 2026 10:10
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 4 Agenus Inc For: 30 June By Investing.com

This article provides a Form 4 filing for Agenus Inc. as of June 30. It is a brief financial update published by Investing.com. The information indicates an insider transaction or change in beneficial ownership for the specified date.

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 10:10
Source
Investing.com Canada